Intranasally administered SARS-CoV-2 RBD-based nanoparticle vaccine provides protection against lung pathology and viral load
In a recent study, researchers working at Ohio State University in the United States of America (USA) developed an intranasal subunit vaccine.
Source: news-medical.net